Johnson & Johnson Competitors

Johnson & Johnson (NYSE:JNJ) and UnitedHealth Group (NYSE:UNH) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider & Institutional Ownership

66.7% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 86.2% of UnitedHealth Group shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by insiders. Comparatively, 0.8% of UnitedHealth Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Johnson & Johnson and UnitedHealth Group's gross revenue, earnings per share and valuation.

UnitedHealth Group has higher revenue and earnings than Johnson & Johnson. Johnson & Johnson is trading at a lower price-to-earnings ratio than UnitedHealth Group, indicating that it is currently the more affordable of the two stocks.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.3%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. UnitedHealth Group pays out 29.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and UnitedHealth Group has raised its dividend for 11 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Johnson & Johnson and UnitedHealth Group, as reported by MarketBeat.com.

Johnson & Johnson currently has a consensus price target of $185.70, suggesting a potential upside of 12.98%. UnitedHealth Group has a consensus price target of $425.1364, suggesting a potential upside of 7.32%. Given Johnson & Johnson's higher probable upside, equities research analysts clearly believe Johnson & Johnson is more favorable than UnitedHealth Group.

Profitability

This table compares Johnson & Johnson and UnitedHealth Group's net margins, return on equity and return on assets.

Risk and Volatility

Johnson & Johnson has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, UnitedHealth Group has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

UnitedHealth Group beats Johnson & Johnson on 10 of the 18 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider and Institutional Ownership

66.7% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 64.2% of Pfizer shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.9%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Pfizer pays out 70.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Profitability

This table compares Johnson & Johnson and Pfizer's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Johnson & Johnson and Pfizer's gross revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Johnson & Johnson has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Johnson & Johnson and Pfizer, as provided by MarketBeat.

Johnson & Johnson currently has a consensus target price of $185.70, suggesting a potential upside of 12.98%. Pfizer has a consensus target price of $39.9286, suggesting a potential upside of 0.93%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts plainly believe Johnson & Johnson is more favorable than Pfizer.

Summary

Johnson & Johnson beats Pfizer on 13 of the 17 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Insider and Institutional Ownership

66.7% of Johnson & Johnson shares are held by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.5%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Eli Lilly and has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Johnson & Johnson and Eli Lilly and's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Johnson & Johnson and Eli Lilly and's revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Johnson & Johnson has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Johnson & Johnson and Eli Lilly and, as reported by MarketBeat.

Johnson & Johnson currently has a consensus price target of $185.70, suggesting a potential upside of 12.98%. Eli Lilly and has a consensus price target of $207.4286, suggesting a potential downside of 8.03%. Given Johnson & Johnson's higher possible upside, research analysts plainly believe Johnson & Johnson is more favorable than Eli Lilly and.

Summary

Eli Lilly and beats Johnson & Johnson on 10 of the 18 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Johnson & Johnson and Novartis, as reported by MarketBeat.

Johnson & Johnson currently has a consensus price target of $185.70, suggesting a potential upside of 12.98%. Novartis has a consensus price target of $108.50, suggesting a potential upside of 16.28%. Given Novartis' higher possible upside, analysts plainly believe Novartis is more favorable than Johnson & Johnson.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.2%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Novartis has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

66.7% of Johnson & Johnson shares are held by institutional investors. Comparatively, 10.1% of Novartis shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Johnson & Johnson has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Earnings and Valuation

This table compares Johnson & Johnson and Novartis' revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Johnson & Johnson and Novartis' net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats Novartis on 15 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for AbbVie and Johnson & Johnson, as reported by MarketBeat.

AbbVie presently has a consensus price target of $119.4615, indicating a potential upside of 4.17%. Johnson & Johnson has a consensus price target of $185.70, indicating a potential upside of 12.98%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than AbbVie.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years and Johnson & Johnson has raised its dividend for 59 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and lower payout ratio.

Insider and Institutional Ownership

66.1% of AbbVie shares are owned by institutional investors. Comparatively, 66.7% of Johnson & Johnson shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

AbbVie has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares AbbVie and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Johnson & Johnson's net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats AbbVie on 10 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Novo Nordisk A/S and Johnson & Johnson, as reported by MarketBeat.

Johnson & Johnson has a consensus price target of $185.70, indicating a potential upside of 12.98%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Novo Nordisk A/S.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.6%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has raised its dividend for 1 consecutive years and Johnson & Johnson has raised its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

5.7% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 66.7% of Johnson & Johnson shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Novo Nordisk A/S has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares Novo Nordisk A/S and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Johnson & Johnson is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novo Nordisk A/S and Johnson & Johnson's net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats Novo Nordisk A/S on 11 of the 17 factors compared between the two stocks.